- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03193463
Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy
Pilot Trial of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy (IND 117,240)
The purpose of this study is to determine if treatment with topotecan by an alternative method, direct delivery into brain tumors, is safe and well tolerated. The Cleveland Multiport Catheter is a new, investigational device that will be used to deliver topotecan into your brain tumor. A second purpose of this study is to determine whether the Cleveland Multiport Catheter can be used effectively and safely to deliver topotecan into your brain tumor.
This study will also determine the best dose of topotecan to deliver to your tumor with use of the Cleveland Multiport Catheter and will also examine how your tumor responds to treatment with topotecan.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Primary Objectives
- To investigate by MR imaging the spatial and temporal distribution of topotecan in enhancing or nonenhancing bulk tumor administered by convection-enhanced delivery (CED) in patients with recurrent/progressive WHO grade III or IV (high grade) glioma (HGG) who have failed standard therapy comprising surgical biopsy and/or resection and adjuvant chemotherapy and radiotherapy.
- To investigate by MR imaging the influence of the rate and topotecan concentration, on the spatial and temporal distribution of topotecan administered by CED in patients with with recurrent/progressive HGG
Secondary Objectives
- To investigate the extent to which backflow may be observed on MRI during CEDmediated delivery of topotecan
- To assess the safety, tolerability and toxicity profile of topotecan administered by CED using different doses and infusion rates.
- To observe evidence of activity of single-agent topotecan administered by CED to patients with recurrent/progressive HGG who have failed standard therapy comprising surgical biopsy and/or resection and adjuvant chemotherapy and radiotherapy.
Studietype
Fase
- Tidlig fase 1
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologically confirmed diagnosis of supratentorial WHO Grade III or IV Glioma (High Grade Glioma) that has undergone surgical biopsy or resection followed by adjuvant chemoradiotherapy, that has evidence of recurrence or progression based on imaging studies and a stereotactic biopsy is indicated for confirmation of recurrence/progression
- Karnofsky Performance Status 70-100
- MRI demonstration of a stereotactically accessible enhancing mass that does not require resection to relieve clinically significant mass effect
- Patient understands the procedures and agrees to comply with the study requirements by providing written informed consent
Laboratory values within the following ranges:
- Absolute neutrophil count (ANC) ≥ 1,500 / μL
- Platelet count ≥ 100,000 / μL
- Hemoglobin ≥ 10 g / dL
- prothrombin time (PT) / partial thromboplastin time (PTT) not above institutional norms
- Estimated glomerular filtration rate (eGFR) of at least 50 mL/min
Exclusion Criteria:
- Patient is mentally or legally incapacitated at the time of the study
- Known HIV(+) or has been diagnosed with AIDS
- Participation in another investigational drug study in the prior 4 weeks
- Positive pregnancy test in a female
- Patient, in the opinion of the investigator, is likely to be poorly compliant
- Diffuse subependymal or cerebrospinal fluid (CSF) disease
- Tumors involving the cerebellum
- Tumor enhancement involving both hemispheres
- Active infection requiring treatment
- Unexplained febrile illness
- Radiation or chemotherapy within 4 weeks of enrollment
- Systemic diseases associated with unacceptable anesthesia or operative risk
- Inability to undergo magnetic resonance imaging
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Predominantly enhancing mass with volume of 8 cc or less
Only 1 Cleveland Multiport Catheter (CMC) will be placed and CED will be performed intra-operatively only in a magnetic resonance imaging (MRI) equipped Operating Room.
Topotecan infusion will be performed over a 4-hour period, with the goal of complete tumor coverage.
The initial rate will be 1.20 ml/hour and infusion will be monitored by intermittent MRI imaging.
The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent.
Following completion of the 4-hour infusion, the CMC will be removed.
The initial rate for each subsequent patient may be adjusted upwards in increments of up to 1.20 ml/hour based upon the tumor coverage and safety characteristics of the previously treated patients.
|
In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered
Andre navn:
an investigational device, will be used to deliver the topotecan
to monitor the infusion of topotecan into the tumor
|
Eksperimentell: Predominantly enhancing mass with volume of > 8 cc
2 Cleveland Multiport Catheter (CMCs) will be placed and the total infusion rate of Topotecan per CMC to be used for the first 24 hours for the first patient will be 0.834 ml/hour (3.48 microliters/minute/microcatheter).
The rate used for the second 24 hours of the infusion will be 1.668 ml/hour.
If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.834 ml/hour.
Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the enhancing tumor by the infused Gadopentetic acid (Gd-DTPA), or 2) rate-limiting toxicity.
|
an investigational device, will be used to deliver the topotecan
to monitor the infusion of topotecan into the tumor
In predominantly enhancing mass with a volume of > 8 cc of topotecan administered.
Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion
Andre navn:
|
Eksperimentell: Predominantly non-enhancing mass
The total infusion rate of Topotecan per Cleveland Multiport Catheter (CMC) to be used for the first 24 hours for the first patient will be 0.29 ml/hour.
The rate used for the second 24 hours of the infusion will be 0.58 ml/hour.
If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.29 ml/hour.
Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the non-enhancing tumor by the infused Gd-DTPA, or 2) rate-limiting toxicity.
|
an investigational device, will be used to deliver the topotecan
to monitor the infusion of topotecan into the tumor
Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of intra-operative catheter related complications
Tidsramme: Up to 12 months
|
Documentation of possible, probable, or definite catheter-related complications
|
Up to 12 months
|
Number of post-operative catheter related complications
Tidsramme: Up to 12 months
|
Documentation of possible, probable, or definite catheter-related complications
|
Up to 12 months
|
Number of catheter related complications after catheter removal
Tidsramme: Up to 12 months
|
Documentation of possible, probable, or definite catheter-related complications
|
Up to 12 months
|
Change in the spatial distribution of intratumorally-administered topotecan at serial timepoints using a gadolinium-based contrast agent, as determined by MRI scan
Tidsramme: Up to 12 months
|
Up to 12 months
|
|
Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion rate, as determined by MRI scan
Tidsramme: Up to 12 months
|
Up to 12 months
|
|
Changes in the spatial distribution of intratumorally-administered topotecan at serial timepoints using volumetric magnetic resonance imaging, as determined by MRI scan
Tidsramme: Up to 12 months
|
Up to 12 months
|
|
Changes in the spatial distribution of intratumorally-administered topotecan at serial timepoints using three-dimensional image reconstruction, as determined by MRI scan
Tidsramme: Up to 12 months
|
Up to 12 months
|
|
Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion concentration, as determined by MRI scan
Tidsramme: Up to 12 months
|
Up to 12 months
|
|
Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion duration, as determined by MRI scan
Tidsramme: Up to 12 months
|
Up to 12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants with response as measured by the Response Assessment in Neuro-Oncology (RANO) Criteria
Tidsramme: Up to 12 months
|
Response includes objective response rate (ORR), median progression-free survival (PFS), proportion progression-free at six months (PFS-6), and median overall survival (OS)
|
Up to 12 months
|
Safety as measured by the common terminology criteria for adverse events (CTCAE)
Tidsramme: Up to 12 months
|
Safety will be determined through adverse events by arm
|
Up to 12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Michael A. Vogelbaum, MD, PhD, Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter histologisk type
- Neoplasmer
- Neoplasmer, kjertel og epitel
- Neoplasmer, Neuroepithelial
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Glioma
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antineoplastiske midler
- Topoisomerasehemmere
- Topoisomerase I-hemmere
- Topotekan
Andre studie-ID-numre
- INFT1317
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Glioma
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Aktiv, ikke rekrutterendeGenmodifiserte T-celler i behandling av pasienter med tilbakevendende eller refraktært malignt gliomTilbakevendende glioblastom | Tilbakevendende ondartet gliom | Ildfast malignt gliom | Tilbakevendende WHO Grad III Gliom | Tilbakevendende WHO grad II Gliom | Ildfast glioblastom | Ildfast WHO Grade II Gliom | Ildfast WHO Grade III GliomForente stater
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics, Inc; Dragon Master FoundationRekrutteringGlioma | Gliom av høy grad | Gliom, ondartet | Diffus gliom | Gliom intrakranieltForente stater
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRekrutteringGlioblastom | Ondartet gliom | Tilbakevendende glioblastom | Tilbakevendende WHO Grad III Gliom | WHO Grad III Gliom | IDH2-genmutasjon | IDH1 genmutasjon | Gliom av lav grad | Tilbakevendende WHO grad II Gliom | WHO Grad II GliomForente stater
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeGlioblastom | Ondartet gliom | WHO Grad III Gliom | Tilbakevendende gliom | Ildfast gliomForente stater
-
Beijing Tiantan HospitalDuke UniversityUkjentGlioblastom | Gliom av høy grad | Gliom, ondartet | Gliom av hjernestammeKina
-
Hospital del Río HortegaFullførtGlioma | Glioblastom | Gliom av lav kvalitet | Gliom, ondartet | Gliom av høy kvalitetSpania
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology ConsortiumRekrutteringGlioblastom | Ondartet gliom | Tilbakevendende glioblastom | Tilbakevendende ondartet gliom | Tilbakevendende grad III Gliom | Grad III GliomForente stater, Australia, Israel, Sveits
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationHar ikke rekruttert ennåGlioma | Gliom av lav kvalitet | Gliom, ondartet | Lavgradig hjernegliom | Gliom intrakranieltForente stater
-
National Cancer Institute (NCI)RekrutteringGlioma | Gliom av høy grad | Ondartet gliom | Gliomer | Gliom av lav gradForente stater
-
Susan ChangGE Healthcare; Sigma-Aldrich; Phillips-MedisizeRekrutteringTilbakevendende WHO Grad III Gliom | WHO Grad III Gliom | WHO Grad II Gliom | Tilbakevendende gliom av grad II fra Verdens helseorganisasjon (WHO).Forente stater
Kliniske studier på Topotecan (<=8cc)
-
Katy PetersGlaxoSmithKline; Schering-PloughFullførtGlioblastom | Gliosarkom | Anaplastisk astrocytomForente stater
-
Xian-Janssen Pharmaceutical Ltd.Avsluttet
-
Fujifilm Pharmaceuticals U.S.A., Inc.RekrutteringAvanserte solide svulsterForente stater
-
Spectrum Pharmaceuticals, IncFullførtSmåcellet lungekreft | Eggstokkreft | Solide svulsterForente stater
-
St. Jude Children's Research HospitalGlaxoSmithKline; National Institutes of Health (NIH)FullførtWilms TumorForente stater, Canada
-
Advenchen Laboratories, LLCAktiv, ikke rekrutterendeEgglederkarsinom | Livmorhalskreft | Endometriekarsinom | Ovariekarsinom | Primært peritonealt karsinomKorea, Republikken, Spania, Forente stater, Storbritannia, Kina, Italia
-
Centre Francois BaclesseGlaxoSmithKline; Centre d'Etudes et de Recherche pour l'Intensification...AvsluttetKreft | Kjemoterapi | Tilbakefall | EggstokkFrankrike
-
Montefiore Medical CenterSanofi; GlaxoSmithKlineFullførtUterine neoplasmer | Neoplasmer i eggstokkeneForente stater
-
Gustave Roussy, Cancer Campus, Grand ParisErasmus Medical Center; Catholic University of the Sacred Heart; St. Anna...FullførtNevroblastom | Solide svulster | HjernesvulsterFrankrike
-
Taiho Oncology, Inc.Taiho Pharmaceutical Co., Ltd.AvsluttetSmåcellet lungekreft (SCLC)Japan, Italia, Tyskland